---
title: "三生制药拟向辉瑞配发 3114.25 万股 净筹约 7.85 亿港元"
description: "三生制药宣布与辉瑞签订许可协议，涉及 PD-1/VEGF 双特异性抗体 (SSGJ-707)。协议自 2025 年 7 月 24 日起生效。辉瑞同意以每股 25.2055 港元的价格认购 3114.25 万股，筹集约 7.85 亿港元，认购价较市场收市价折让约 17.09%。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/249949092.md"
published_at: "2025-07-24T11:32:02.000Z"
---

# 三生制药拟向辉瑞配发 3114.25 万股 净筹约 7.85 亿港元

> 三生制药宣布与辉瑞签订许可协议，涉及 PD-1/VEGF 双特异性抗体 (SSGJ-707)。协议自 2025 年 7 月 24 日起生效。辉瑞同意以每股 25.2055 港元的价格认购 3114.25 万股，筹集约 7.85 亿港元，认购价较市场收市价折让约 17.09%。

智通财经 APP 讯，三生制药 (01530) 发布公告，有关 (其中包括) 与辉瑞就 PD-1/VEGF 双特异性抗体 (SSGJ-707) 订立许可协议。

许可协议所订明的所有先决条件已达成，因此，许可协议自 2025 年 7 月 24 日起生效。

于 2025 年 7 月 24 日 (交易时间后)，公司与辉瑞订立认购协议，据此，辉瑞已有条件同意认购而公司已有条件同意发行及配发 3114.25 万股认购股份，认购价为每股 25.2055 港元，总金额约为 7.85 亿港元。每股认购股份的认购价较股份于认购协议日期在联交所所报的收市价每股 30.40 港元折让约 17.09%。

### Related Stocks

- [01530.HK - 三生制药](https://longbridge.com/zh-CN/quote/01530.HK.md)
- [PFE.US - 辉瑞](https://longbridge.com/zh-CN/quote/PFE.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Pfizer Targets Real-World Myeloma Data in Taiwan With New Elranatamab Study | Pfizer Inc. (PFE) is launching a new observational study in Taiwan to evaluate the effectiveness of its multiple myeloma | [Link](https://longbridge.com/zh-CN/news/276252273.md) |
| How PTC’s (PTC) New FlexPLM Win with SPG Shapes Its Intelligent PLM Investment Story | PTC announced that SPG Company selected its FlexPLM solution to modernize product lifecycle operations, enhancing data a | [Link](https://longbridge.com/zh-CN/news/276294946.md) |
| CICC Reaffirms Their Buy Rating on Suzhou Ribo Life Science Co., Ltd. Class H (6938) | In a report released yesterday, from CICC maintained a Buy rating on Suzhou Ribo Life Science Co., Ltd. Class H, with a  | [Link](https://longbridge.com/zh-CN/news/276199846.md) |
| Kratos Defense & Security Solutions Officer Sells Shares | Phillip D Carrai, President of the STC Division at Kratos Defense & Security Solutions, sold 6,500 shares of common stoc | [Link](https://longbridge.com/zh-CN/news/276398029.md) |
| FirstService: Capitalizing on Cyclical Dislocation with Durable Growth and Conservative 2026 Upside | William Blair analyst Stephen Sheldon has reiterated a Buy rating on FirstService (FSV) stock, citing confidence in the  | [Link](https://longbridge.com/zh-CN/news/276281132.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。